Research Study Available in Baltimore, Dorchester, and Lima for Lesser-Known ‘Bad’ Cholesterol Called Lp(a)

BALTIMORE — (BUSINESS WIRE) - A cardiovascular research study is now available in Baltimore, Md., for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a). Elevated Lp(a) is recognized by healthcare professionals as an important risk factor for cardiovascular disease. However, Lp(a) is often not tested for—and testing is often not covered by insurance—because there are no currently approved treatments for lowering Lp(a). Participants in this study will receive Lp(a) tests at no cost.

Lp(a) is similar to “bad” LDL cholesterol, but has an extra protein that hangs off LDL cholesterol particles. This makes it even stickier than LDL and more likely to cause blockages and blood clots in blood vessels. Heart attack or stroke are some of the serious and, unfortunately, common cardiovascular events associated with elevated Lp(a). According to the Baltimore City Health Department, heart disease is the leading cause of death and stroke is the third leading cause of death in Baltimore.

KRAKEN is a phase 2 study to assess the efficacy of a new investigational treatment developed to safely and effectively lower Lp(a) in individuals at high risk for cardiovascular events

“It’s estimated that about one in five people in the world have elevated Lp(a) levels with Black people of sub-Saharan descent and South Asians exhibiting even higher rates,” said Dr. Ali Bajwa, Principal Investigator of Care Access - Baltimore. “Since elevated Lp(a) is thought to be genetically derived, normal courses of action to treat high cholesterol like eating a healthier diet, exercise, and weight loss have little to no effect on Lp(a) levels. That’s why I am very excited to help bring this Lp(a) screening opportunity and investigational treatment to the Baltimore community as a part of this far-reaching study.”

The research study is currently enrolling for adults ages 40+ with elevated Lp(a) and at high risk for cardiovascular events. To learn more about this study, visit knowmylpa.com or contact Care Access at (351) 222-5112

Care Access opened its Baltimore location in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible to the Baltimore community.

DORCHESTER, MASS. — (BUSINESS WIRE) - A cardiovascular research study is now available in Dorchester for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a). Elevated Lp(a) is recognized by healthcare professionals as an important risk factor for cardiovascular disease. However, Lp(a) is often not tested for—and testing is often not covered by insurance—because there are no currently approved treatments for lowering Lp(a). Participants in this study will receive Lp(a) tests at no cost.

Lp(a) is similar to “bad” LDL cholesterol, but has an extra protein that hangs off LDL cholesterol particles. This makes it even stickier than LDL and more likely to cause blockages and blood clots in blood vessels. Heart attack or stroke are some of the serious and, unfortunately, common cardiovascular events associated with elevated Lp(a).

KRAKEN is a phase 2 study to evaluate the efficacy of this new investigational treatment developed to safely lower Lp(a) in individuals at high risk for serious cardiovascular events.

“Elevated Lp(a) is believed to be inherited from one’s parents, so it can affect multiple members of the family,” said Dr. Peta-Gay Jackson Booth, Principal Investigator of Care Access - Dorchester. “About one in five people have elevated Lp(a) levels, and it’s even more prevalent in Black people and South Asians. That’s why it’s important to offer this study and screening opportunity in diverse communities like Dorchester.”

The research study is currently enrolling for adults ages 40+ with elevated Lp(a) and at high risk for cardiovascular events. To learn more about this study, visit knowmylpa.com or contact Care Access at (351) 222-5112.

Care Access opened its Dorchester location in 2022 in collaboration with local community leaders and healthcare providers seeking to make clinical research more easily accessible.

LIMA, OHIO — (BUSINESS WIRE) - A cardiovascular research study is now available in Lima for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a). Elevated Lp(a) is recognized by healthcare professionals as an important risk factor for cardiovascular disease. However, Lp(a) is often not tested for—and testing is often not covered by insurance—because there are no currently approved treatments for lowering Lp(a). Participants in this study will receive Lp(a) tests at no cost.

Lp(a) is similar to “bad” LDL cholesterol, but has an extra protein that hangs off LDL cholesterol particles. This makes it even stickier than LDL and more likely to cause blockages and blood clots in blood vessels. Heart attack or stroke are some of the serious and, unfortunately, common cardiovascular events associated with elevated Lp(a).

KRAKEN is a phase 2 study to evaluate the efficacy of this new investigational treatment developed to safely and effectively lower Lp(a) in individuals at high risk for cardiovascular events

“Since elevated Lp(a) is thought to be inherited, normal courses of action to treat high cholesterol like eating a healthier diet, exercise, and weight loss have little to no effect on Lp(a) levels,” said Dr. Ali Bajwa, Principal Investigator of Care Access - Lima. “This study will help contribute to our understanding of how to keep Lp(a) within a normal range.”

The research study is currently enrolling for adults ages 40+ with elevated Lp(a) and at high risk for cardiovascular events. To learn more about this study, visit knowmylpa.com or contact Care Access at (419) 500-9330.

Care Access opened its Lima location in March 2022 in collaboration with local community leaders and healthcare providers seeking to bring clinical research opportunities to the Lima community.